NEW YORK, March 26, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Endocyte, Inc. (NASDAQ: ECYT), Ophthotech Corporation (NASDAQ:
OPHT), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), bluebird bio,
Inc. (NASDAQ: BLUE), and Cantel Medical Corp. (NYSE: CMN). Private
wealth members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
Endocyte, Inc. Analyst Notes
On March 21, 2014, Endocyte, Inc.
(Endocyte) announced results from its Phase 2b TARGET trial, which
showed that the study met the primary endpoint for the combination
of vintafolide (EC145/MK-8109) and docetaxel in folate receptor
(FR)-positive recurrent non-small cell lung cancer (NSCLC)
patients. According to the Company, the data showed that risk of
disease worsening or death was reduced by 25% for patients treated
with the vintafolide/docetaxel combination versus docetaxel alone.
Binh Nguyen, M.D., Ph.D., Vice
President of Medical Affairs at Endocyte, stated, "We are pleased
with the results of this study, as the vintafolide/docetaxel
combination showed meaningful activity in patients with recurrent
NSCLC, meeting the primary endpoint of the trial. We were
especially pleased with the results in the adenocarcinoma
population and early OS trends, and we have learned important
information about the dosing schedule. We look forward to reviewing
additional analysis of this study when the OS data has matured
later this year to help inform potential further development of the
vintafolide/docetaxel combination in NSCLC." The full analyst notes
on Endocyte, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03262014/ECYT/report.pdf
--
Ophthotech Corporation Analyst Notes
On March 21, 2014, Ophthotech
Corporation's (Ophthotech) stock went down by 5.32%, closing at
$35.96. However, in the past three
months Ophthotech shares went up by 15.93%, compared to the Nasdaq
Composite which went up by 4.19% during the same trading period.
The full analyst notes on Ophthotech Corporation are available to
download free of charge at:
http://www.AnalystsReview.com/03262014/OPHT/report.pdf
--
AcelRx Pharmaceuticals, Inc. Analyst Notes
On March 21, 2014, AcelRx
Pharmaceuticals, Inc.'s (AcelRx Pharmaceuticals) stock went down by
3.63%, closing at $12.47. Over the
past five trading days, the Company's stock went up by 0.16%,
compared to the Nasdaq Composite Index which went up by 0.74%
during the same trading period. The full analyst notes on AcelRx
Pharmaceuticals, Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/03262014/ACRX/report.pdf
--
bluebird bio, Inc. Analyst Notes
On March 5, 2014, bluebird bio,
Inc. (bluebird bio) reported its full-year 2013 financial results.
Total revenues for full year 2013 were $20.2
million, compared to total revenues of $0.3 million in full year 2012. Net loss
applicable to common stockholders for full year 2013 was
$25.3 million or $2.02 per diluted share, compared to full-year
2012 net loss applicable to common stockholders of $3.6 million or $13.79 per diluted share. Commenting on the
results, Nick Leschly, Chief
bluebird bio, stated, "In 2013 we transplanted the first patients
in our phase 2/3 Starbeam study for CCALD and our phase 1/2 HGB-205
study for beta thalassemia and sickle cell disease. This was a
considerable accomplishment for all those involved in these
studies. Earlier in the year, we leveraged our lentiviral platform,
signing a multi-year collaboration with Celgene in the exciting
area of CAR T for oncology, which strengthened our balance sheet
and further validated our lentiviral platform. In June, we
completed a successful IPO, setting the stage for the next
evolution in the bluebird story. We look forward to another
productive year in 2014." The full analyst notes on bluebird bio,
Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03262014/BLUE/report.pdf
--
Cantel Medical Corp. Analyst Notes
On March 11, 2014, Cantel Medical
Corp. (Cantel Medical) reported its Q2 FY 2014 and H1 FY 2014
(period ended January 31, 2014)
financial results. Net sales for Q2 FY 2014 went up by 11.9% YoY to
$119.0 million, and H1 FY 2014 net
sales went up by 15.2% YoY to $237.3
million. Net income for Q2 FY 2014 was $11.1 million or $0.27 per diluted share, compared to net income
of $10.5 million or $0.25 per diluted share in Q2 FY 2013. H1 FY 2014
net income was $22.3 million or
$0.54 per diluted share, compared to
net income of $20.0 million or
$0.49 per diluted share in H1 FY
2013. Commenting on the results, Andrew
Krakauer, Cantel Medical's President and CEO, stated, "We
are pleased to have delivered record sales and solid earnings
performance in the second quarter. These positive results confirm
the continued success of our strategic approach to growth which
includes investing in new product development, sales and marketing
programs and acquisitions." The full analyst notes on Cantel
Medical Corp. are available to download free of charge at:
http://www.AnalystsReview.com/03262014/CMN/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
-
For any urgent concerns or inquiries,
please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review